|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
30 April 2018 |
|
Main ID: |
ChiCTR1800015677 |
|
Date of registration:
|
2018-04-14 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Clinical study for the effect of salvianolic acid on plaque stability and angiogenesis
|
|
Scientific title:
|
Clinical study for the effect of salvianolic acid on plaque stability and angiogenesis |
|
Date of first enrolment:
|
2018-04-15 |
|
Target sample size:
|
salvianolic acids:20;Routine treatment control group:20; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=26311 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Post-market
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Wang Yan
|
|
Address:
|
29 Twin Towers Temple Street, Taiyuan, Shanxi, China
030000
|
|
Telephone:
|
+86 18435149593 |
|
Email:
|
1458536601@qq.com |
|
Affiliation:
|
Shanxi Medical University |
|
|
Name:
|
Hu Fengyun
|
|
Address:
|
29 Twin Towers Temple Street, Taiyuan, Shanxi, China
030000
|
|
Telephone:
|
+86 13834233638 |
|
Email:
|
fengyun71@163.com |
|
Affiliation:
|
Shanxi People's Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. aged 40-75 years old;
2. patients with large area cerebral infarction within 72 hours of onset;
For the first time in 3. cerebral vascular disease, or had a history of cerebrovascular disease, but did not have limb paralysis sequelae, and does not affect the NIHSS score, mRS score before the onset of stroke is less than or equal to 2 points;
4. large area cerebral infarction of internal carotid artery system by cranial nuclear magnetic DWI examination;
5. in the case of informed consent, we can accept and cooperate with blood test, NMR and TCD examination. The sample content was 40 cases.
Exclusion criteria: 1. History of neurologic disease;
2. There was a history of severe hypertension, diabetes and connective tissue disease. Vascular examination showed obvious atherosclerosis, especially in severe arterial stenosis;
3. Complication of severe liver and kidney function;
4. Recent history of surgery;
5. Contraindication with magnetic resonance imaging;
6. Anaphylaxis to Salvia miltiorrhiza.
Age minimum:
40
Age maximum:
75
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
massive cerebral infarction
|
|
Intervention(s)
|
|
salvianolic acids:application of injection salvianolic acids;Routine treatment control group:General routine treatment after cerebral infarction;
|
|
Primary Outcome(s)
|
|
MRI-ASL;MRI-DWI;VEGF;bFGF;
|
|
Source(s) of Monetary Support
|
|
Wu Jieping medical foundation
|
|
Ethics review
|
Status: Not approved
Approval date: 26/08/2013
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|